Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 3/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 12/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.34 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28592176 | 1.00 | F11 (0.38) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL616978 | 0.92 | AAK1 (0.34) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL16974676 | 0.89 | F11 (0.42) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL15915827 | 0.89 | F11 (0.38) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL15915824 | 0.89 | F11 (0.38) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL18690161 | 0.88 | AAK1 (0.36) | F11AAK1 | |
| SCHEMBL18690163 | 0.88 | AAK1 (0.36) | F11AAK1 | |
| SCHEMBL30193841 | 0.88 | AAK1 (0.36) | F11AAK1 | |
| SCHEMBL16983835 | 0.87 | AAK1 (0.35) | AAK1 | |
| SCHEMBL15594121 | 0.86 | AAK1 (0.34) | F11AAK1MAP4K4HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404274-B2 | Macrocycles as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-02-23 | — | — | US | disclosed |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-05 | — | — | US | disclosed |
| CN-108250199-B | Dihydropyridone P1 as factor XIA inhibitor | 百时美施贵宝公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-3786165-A1 | SYNTHETIC INTERMEDIATES FOR PRODUCING MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-2534154-B1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-05 | — | — | EP | disclosed |
| US-20200087312-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3099686-B1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-11 | — | — | EP | disclosed |
| EP-3070087-B1 | INTERMEDIATES FOR THE SYNTHESIS OF CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-8901115-B2 | Cyclic P1 linkers as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140221338-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140163002-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2739628-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-06-11 | — | — | EP | disclosed |
| US-20140038969-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-02-06 | — | — | US | disclosed |
| WO-2014022766-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2013022818-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-14 | — | — | WO | disclosed |
| EP-2534154-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-16 | — | — | US | disclosed |
| WO-2011100401-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | F11 3/4885KLKB1 13/4885PRSS1 44/4885 |
| US-20200087312-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | F11 3/4885KLKB1 13/4885PRSS1 44/4885 |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | TFPI, TFPI2, F12 | F11 4/4885KLKB1 14/4885PRSS1 46/4885 |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | TFPI, TFPI2, F11 | F11 3/4885KLKB1 13/4885PRSS1 44/4885 |
| US-20140038969-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | F11 3/4885KLKB1 7/4885PRSS1 28/4885 |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | TFPI, TFPI2, F11 | F11 3/4885KLKB1 13/4885PRSS1 44/4885 |
| US-20140221338-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | F11 4/4885KLKB1 12/4885PRSS1 45/4885 |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | F11 3/4885KLKB1 13/4885PRSS1 44/4885 |
| US-20140163002-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | F11, F12, F13A1 | F11 1/4885KLKB1 10/4885PRSS1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.